Covid-19 et remdesivir : Lettre ouverte de Daniel O’Day, CEO de Gilead Sciences 4 avril 2020. Au cours de la semaine dernière, Gilead a travaillé, en collaboration avec les autorités de santé, à la mise en place de programmes d'accès complémentaires pour mettre à disposition des patients, notre médicament expérimental…..
Remdesivir and Covid-19: an update from Daniel O'Day, chairman and CEO of Gilead April 04, 2020. Over the course of the past week, Gilead has been working in consultation with regulatory authorities to establish additional expanded access programs for remdesivir, our investigational medicine for COVID-19. The programs enable hospitals or…..
FEATURE STORY ● Impact of gene therapy for canine monogenic diseases on the progress of preclinical studies GENE THERAPY ● Permanent inactivation of HBV genomes by CRISPR/Cas9-mdediated non cleavage base editing DISRUPTIVE TECHNOLOGIES ● Hydroxybutyl chitosan centered biocomposites for potential curative applications ● CAR-T treatment for hematological malignancies ● Anti-CRISPRs :…..
Trend Chart on Orphans - February 15th, 2020 FEATURE STORY ● The potential of gene therapy for mucopolysaccharidosis type I GENE THERAPY ● Repair of retinal degeneration following ex vivo Minicircle DNA gene therapy and transplantation of corrected photoreceptor progenitors RARE DISEASES ● Genetics and other omics in pediatric pulmonary…..
Trend Chart on Innovative Biotherapies - January 15th, 2020 FEATURE STORY ● The National Gene Vector Biorepository. Eleven years of providing resources to the gene therapy community GENE THERAPY ● Recommendations for the development of cell-based anti-viral vector neutralizing antibody assays DISRUPTIVE TECHNOLOGIES ● A small molecule-controlled Cas9 repressible system…..
Morpholino technology could allow control of gene therapy doses Scientists at Scripps Research, led by principal investigator Michael Farzan, have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing. The feat, reported in Nature Biotechnology, offers gene therapy designers what may…..
FEATURE STORY ● Artificial intelligence approach to create AAV capsids for gene therapies DISRUPTIVE TECHNOLOGIES ● Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier CLINICAL TRIALS - DATAS ● Libella gene therapeutics to run a patient paid trial of telomerase gene therapy M&A - AGREEMENTS ●…..
An artificial intelligence approach to create AAV capsids for gene therapies Adeno-associated viruses (AAVs) have become the go-to vehicle for delivering therapeutic gene cargo to target tissues for the recent wave of gene therapies that are in development in academic and biotechnology laboratories (1). However, natural AAVs do not specifically…..
Two Chinese companies invest in Vigeneron, a German firm developing ophthalmological gene therapy programs The German gene therapy company Vigeneron has closed a series A financing round led by WuXi AppTec, a Chinese provider of R&D and manufacturing services and Sequoia Capital China, a venture capital firm based in Beijing.…..
More than 580 gene therapy products are under development in biotech and pharmaceutical companies for the treatment of more than 240 diseases. More than 200 of these products are now at the clinical stage. After releasing our « Landscape in… Gene Therapy Companies » in September, we now offer you an opportunity…..
- 1
- 2
- 3
...
- 26
- Page Suivante
Partenaires
